(Q36548338)

14 August 2017

1 reference

title

The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity? (English)

1 reference

14 August 2017

1 reference

0 references

kidney transplantation

1 reference

Knight RJ

1

1 reference

14 August 2017

Kahan BD

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

26 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

70

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

994-999

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ki.5001644

14 August 2017

exact match

0 references

cites work

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

The effect of rapamycin on kidney function in the Sprague-Dawley rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Toxicity of rapamycin--a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Correlation between cyclosporine-induced nephrotoxicity in reduced nephron mass and expression of kidney injury molecule-1 and aquaporin-2 gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001644

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5001644

1 reference

Dimensions Publication ID

14 August 2017

1047289802

0 references

1 reference